Ochsendorf F R, Sachsenberg-Studer E M, Grundmann-Kollmann M, Podda M, Milbradt R, Krutmann J, Kaufmann R
Zentrum der Dermatologie und Venerologie, Klinikum der J.W. Goethe-Universität, Frankfurt.
Hautarzt. 2000 Feb;51(2):79-81. doi: 10.1007/s001050050016.
Ultraviolet (UV-) radiation therapy as a mono- or combination therapy (UV-A, UV-A1, UV-B, SUP, UV-B311) or as photochemotherapy with photosensitization (systemic PUVA-, bath PUVA-, topical PUVA-therapy) are successfully used for the treatment of several dermatological disorders. Long-term side effects of natural UV (sun light) include photoaging and induction of skin tumors. At present, the relevance of in-vitro findings of potential tumor induction in animals through therapeutic levels of UV radiation is a matter of debate. To assess these risks, information on treated location, kind of UV radiation and cumulative UV doses are required. Practically this information is barely accessible. This makes decisions on possible therapies difficult. To solve this problem we propose to use an "UV pass". At the end of each UV radiation cycle, the body location, the type of radiation and the cumulative dose are documented and this pass is given to the patient. This will improve the information transfer if the doctor is changed, as well as facilitating decisions about certain therapies and calculation of long-term risks of UV radiation. Finally it will improve the quality of UV photo- and photochemotherapy.
紫外线（UV）辐射疗法作为单一疗法或联合疗法（UV-A、UV-A1、UV-B、SUP、UV-B311），或作为光敏化光化学疗法（全身补骨脂素紫外线A疗法、药浴补骨脂素紫外线A疗法、局部补骨脂素紫外线A疗法）已成功用于治疗多种皮肤病。天然紫外线（阳光）的长期副作用包括光老化和诱发皮肤肿瘤。目前，关于治疗水平的紫外线辐射在动物体内潜在诱发肿瘤的体外研究结果的相关性存在争议。为评估这些风险，需要了解治疗部位、紫外线辐射类型和累积紫外线剂量的信息。实际上，这些信息很难获取。这使得关于可能的治疗方法的决策变得困难。为解决这个问题，我们建议使用“紫外线通行证”。在每个紫外线辐射周期结束时，记录身体部位、辐射类型和累积剂量，并将此通行证交给患者。如果更换医生，这将改善信息传递，同时便于做出关于某些治疗方法的决策以及计算紫外线辐射的长期风险。最后，它将提高紫外线光疗和光化学疗法的质量。
